Real-life underuse of SGLT2 inhibitors for patients with type 2 diabetes at high cardiorenal risk

Scheen, André J.

doi:10.1016/j.deman.2023.100184

Cited by 4 publications

(1 citation statement)

References 71 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite the positive effects of SGLT-2 inhibitors in clinical trials, real-world data are also crucial to evaluate their effectiveness and safety in everyday clinical practice, as well as patients’ accessibility to treatment. A recent study demonstrated the underuse of these medications in patients with T2DM and the increased cardiorenal risk [ 73 ]. Finally, their impact on other cardiovascular situations that cause myocardial fibrosis and HF, like ST-elevation myocardial infarction or arrhythmias, requires more intensive investigation [ 74 ].…”

Section: Gaps In Evidence and Future Researchmentioning

confidence: 99%

The Role of Sodium-Glucose Co-Transporter-2 Inhibitors on Diuretic Resistance in Heart Failure

Stachteas,

Nasoufidou,

Patoulias

et al. 2024

IJMS

View full text Add to dashboard Cite

Heart failure (HF) remains a major cause of morbidity and mortality worldwide. Recently, significant advances have been made in its treatment; however, diuretics remain the cornerstone in managing congestion in HF. Although diuretic resistance poses a significant challenge in the management of HF and is associated with poor outcomes, only limited alternative pharmaceutical options are available in clinical practice. The objective of this narrative review is to provide a comprehensive analysis of the current evidence on the effects of sodium-glucose co-transporter-2 (SGLT-2) inhibitors on diuretic resistance in HF patients. The primary emphasis is placed on clinical data that assess the impact of SGLT-2 inhibitors on fluid balance, symptom improvement, and clinical outcomes and secondarily on safety profile and potential adverse effects associated with SGLT-2 inhibitor use in acute decompensated HF. The current evidence on the efficacy of SGLT-2 on diuretic resistance remains controversial. Findings from observational and randomized studies are quite heterogenous; however, they converge on the notion that although SGLT-2 inhibitors show promise for mitigating diuretic resistance in HF, their diuretic effect may not be potent enough to be widely used to relieve objective signs of congestion in patients with HF. Importantly, the introduction of SGLT-2 inhibitors in HF treatment appears to be generally well tolerated, with manageable adverse effects. Further research is needed to investigate the underlying mechanisms and the possible beneficial impact of SGLT-2 inhibitors on diuretic resistance in HF.

show abstract

Section: Gaps In Evidence and Future Researchmentioning

confidence: 99%

The Role of Sodium-Glucose Co-Transporter-2 Inhibitors on Diuretic Resistance in Heart Failure

Stachteas,

Nasoufidou,

Patoulias

et al. 2024

IJMS

View full text Add to dashboard Cite

show abstract

Paradoxical real-life underuse of GLP-1 receptor agonists in type 2 diabetes patients with atherosclerotic cardiovascular disease

Scheen

2024

Diabetes Epidemiology and Management

View full text Add to dashboard Cite

Underuse of GLP-1 receptor agonists in the management of type 2 diabetes despite a favorable benefit-safety profile

Scheen

2024

Expert Opinion on Drug Safety

View full text Add to dashboard Cite

Real-life underuse of SGLT2 inhibitors for patients with type 2 diabetes at high cardiorenal risk

Cited by 4 publications

References 71 publications

The Role of Sodium-Glucose Co-Transporter-2 Inhibitors on Diuretic Resistance in Heart Failure

The Role of Sodium-Glucose Co-Transporter-2 Inhibitors on Diuretic Resistance in Heart Failure

Paradoxical real-life underuse of GLP-1 receptor agonists in type 2 diabetes patients with atherosclerotic cardiovascular disease

Underuse of GLP-1 receptor agonists in the management of type 2 diabetes despite a favorable benefit-safety profile

Contact Info

Product

Resources

About